They are rushing at breakneck speed to develop, manufacture and prepare a Vaccine for COVID 19 by the end of the year. That is insane. There is no way on earth, no matter what advances they have had in science, that a drug of any kind let alone a VACCINE can be fully tested and verified in that short a time. Even if they had it already in production before we knew there was a virus.
It is time that the public take a serious look at the companies that are working on this vaccine. In this post, we will look at the primary candidates.
ORDER WHILE YOUR ABLE https://mypatriotsupply.com/pages/rs-repdig-richie-from-boston?rfsn=1750310.2a7b74&subid=RFB.Richie.From.Boston&gclid=Cj0KCQiAtrnuBRDXARIsABiN-7DvezedPsuH5GU2YoCyyBlLQIPOyimzBAmCRDvFQfRBtk5_tkSX0xoaAhc9EALw_wcBhttp://www.preparewithrichie.com
RFB ON TWITTER https://twitter.com/NULOOKREFINISH
RFB II RICHIEFROMBOSTON II https://www.youtube.com/watch?v=N7xZ9w4i5jI&t=5458s
DAYZOFNOAH PROFUSA https://www.youtube.com/watch?v=w32PXElCves
In this video Bill gates proudly explains that his 10 billion dollar investment in the vaccine industry has gotten him a yield of about 20 times his initial investment. Admitting that he is not so much a philanthropist but more of a cutthroat businessman.
More videos on many conspiracies on The Myth Website
Epstein and Pedophilia https://themyth.net/library/pedophilia-2/
Evil Elites and control https://themyth.net/library/elite-families-and-bloodlines/
Climate controversy https://themyth.net/library/climate-controversy/
Check out The Myth Website on
www.themyth.net 1 year, 2 months ago
Corey Lynn from CoreysDigs.com rejoins the program to discuss the flow of money between the Bill and Melinda Gates Foundation and their non profit trust and companies. We also discuss the World Health Association and other institutions & characters in the global health industry. When you follow the money, a bigger picture and agenda takes shape. See more of Corey Lynn’s great journalism @ http://CoreysDigs.com
Support Patriots & Independent Journalism @ http://GreenPillLiving.com/Westall – Use code “Westall” & save 10% as a first time buyer! Find quality CBD oil, Collidial Silver, & much more!
Find any of the products mentioned & support the show @ http://SarahWestall.com/Shop
Follow me on Twitter @ https://twitter.com/westall_sarahw
Censorship is serious. To stay informed of all the latest episodes, sign up for my weekly newsletter @ http://SarahWestall.com
MUSIC CREDITS: “A Tale of Vengeance” by Aakash Gandhi licensed for broad internet media use, including video and audio
Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use.
Disclaimer: “As a journalist, I report what significant newsmakers are claiming. I do not have the resources or time to fully investigate all claims. Stories and people interviewed are selected based on relevance, listener requests, and by suggestions of those I highly respect. It is the responsibility of each viewer to evaluate the facts presented and then research each story further and come to their own conclusions.” 1 year, 4 months ago
Many of us were not aware of Bill Gates and his plans for the global community before the coronavirus pandemic.
But Gates has made headlines in the past several months and his vaccine agenda for the human race has been exposed.
“Our healthy and delicious storable foods are now available with the shortest lead time we’ve had in months!”
https://www.infowarsstore.com/health-and-wellness/food?ims=czxxc&utm_campaign=foodbis&utm_source=bitchute&utm_medium=Text+Link&utm_content=foodbis 12 months ago
None 1 year, 3 months ago
Astrazeneca signs deal for 400ml doses off covid-19 vaccine with EU
From Pfizer to Moderna: who’s making billions from Covid-19 vaccines?
The companies in line for the biggest gains – and the shareholders who have already made fortunes
Among the biggest winners will be Moderna and Pfizer – two very different US pharma firms which are both charging more than $30 per person for the protection of their two-dose vaccines. While Moderna was founded just 11 years ago, has never made a profit and employed just 830 staff pre-pandemic, Pfizer traces its roots back to 1849, made a net profit of $9.6bn last year and employs nearly 80,000 staff.
But other drugmakers, such as the British-Swedish AstraZeneca and the US pharma Johnson & Johnson, have pledged to provide their vaccines on a not-for-profit basis until the pandemic comes to an end.
Whether the market remains a money-spinner in the future depends on whether the vaccines become the type that need just a one-off shot – as for measles – or if regular vaccinations will be required, such as for flu. But in the immediate future, there are big financial returns up for grabs.
Here, we look at who is in line for the biggest gains – and which shareholders have already made fortunes.1
Pfizer’s Comirnaty vaccine, developed with Germany’s BioNTech, is based on re-engineered messenger RNA – the molecule that sends genetic instructions from DNA to a cell’s protein-making machinery. It was the first to be approved and has to be stored at ultra-low temperatures (-70C). Governments have ordered about 780m shots, including the US (200m doses for $3.9bn) and the EU commission (300m), while 40m doses will go to lower-income nations via the Covax facility. It costs $39 (£28) for two doses in the US and about $30 in the EU.
Expected sales in 2021: $15bn-$30bn
Pfizer, which splits costs and profit margins equally with BioNTech, expects $15bn in 2021 sales based on current deals. The final number could be twice as high, as Pfizer says it can potentially deliver 2bn doses this year. Barclays analyst Carter Gould is predicting sales of $21.5bn in 2021, $8.6bn next year and $1.95bn in 2023, on the assumption that the jab is given as a one-off shot.
Share price change over the past 12 months
The two founders of BioNTech, the husband and wife team Ugur Sahin and Özlem Türeci – both doctors – became multibillionaires last year, when the potential of the vaccine and the deal with Pfizer prompted the shares to surge.2
The vaccine produced by the US biotech firm, based in Massachusetts, must be stored at freezer temperature (-20C). The UK has ordered 17m doses, the EU bought 310m with an option for a further 150m in 2022, while the US government ordered 300m shots. Japan purchased 50m shots. Moderna charges $30 for the required two shots in the US and $36 in the EU.
Expected sales in 2021: $18bn-$20bn
Moderna has said it expects 2021 sales of $18.4bn. Barclays analyst Gena Wang forecasts sales of $19.6bn, $12.2bn in 2022, and $11.4bn in 2023, assuming recurring vaccinations.
Share price change over past 12 months
A group of investors that backed the company when it was founded in 2010 will have made substantial returns. The chief executive, Stéphane Bancel, a 48-year-old French executive, owns 9% of the shares, now worth nearly $5bn.3
J&J’s jab, the world’s first single-shot Covid-19 vaccine, was developed by its Janssen division in Belgium. It uses adenovirus-26, a rare variant of cold virus. It was approved in the US in late February and can be stored at standard fridge temperatures for at least three months. Big orders include the US, UK (30m doses plus option for 22m), the EU (up to 400m doses), and Covax nations (500m doses through 2022).
Expected sales in 2021: up to $10bn
The company aims to deliver at least 1bn doses this year, which would generate $10bn. The US government has ordered 100m doses, with the option to buy 200m more, and is paying $10 a shot.
Share price change over past 12 months
The vaccine developed with Oxford University uses a modified chimpanzee cold virus and can be kept at fridge temperature. Viral vector vaccines use a harmless virus to deliver a piece of genetic code to cells. Big orders have come from the UK (100m), the EU (up to 400m), the US (300m) and Japan (£120m).
Expected sales in 2021: $2bn-$3bn
Analysts at SVB Leerink are forecasting sales of $1.9bn this year and $3bn in 2022. The 2021 figure could be far higher if AstraZeneca achieves its ambitious target of 3bn doses. The company has pledged to supply the vaccine on a not-for-profit basis during this pandemic, and charges $4.30 to $10 for two doses.
Share price change in last 12 months 8.6%5
The CoronaVac jab has been administered for emergency use in several Chinese cities since last summer, and was approved by China’s regulator in early February. Sinovac, which is based in Beijing, has struck deals with Brazil, Chile, Singapore, Malaysia and the Philippines. In January, Turkey and Indonesia kicked off their vaccination campaigns with the jab. Sinovac also plans to supply 10m vaccine doses to Covax nations.
Expected sales in 2021: billions of dollars, but unclear
Sinovac says it can produce more than 1bn doses this year. The vaccine has been priced at $60 for two shots in some Chinese cities. Sinovac’s Indonesian partner Bio Farma, which has ordered at least 40m doses, said it would cost $27.20 for two doses locally.
Share price change in last 12 months 21.6%6
Although it has not been approved by the EU regulator yet, Hungary and Slovakia have bought the Russian vaccine Sputnik V. In total, more than 50 countries, including Iran, Algeria and Mexico, have ordered it. AstraZeneca is testing a two-shot combination of its vaccine with Sputnik.
Expected sales in 2021: unclear but possibly billions
The developers are struggling to mass-produce Sputnik in Russia, but RDIF, a sovereign wealth fund, told the Financial Times last month that it had signed contracts with 15 manufacturers in 10 countries to produce 1.4bn jabs. The developers have said they would charge $20 or less for the required two doses internationally but are providing it free in Russia.7
The Novavax vaccine uses a small fragment of a lab-made version of the Sars-CoV-2 spike protein. The US firm hopes for regulatory approval in the UK, US and other countries in the first half. The company has been researching vaccines for more than 30 years and has never before had a jab approved. It has agreed to supply 300m doses so far, including the UK (60m doses), EU, Canada and Australia. It hopes to produce 150m doses a month and is expected to be cheaper than rivals. According to the Financial Times, the company has agreed to charge $3 a shot in Africa. The vaccine will also be made in Stockton-on-Tees, in north-east England, and can be be kept at fridge temperature.
Expected sales in 2021: ‘several billion dollars’
Based on these deals, Novavax said this week it sees “the potential for several billion dollars in revenue in the next 12 months”. This is set to rise, as Novavax expects to be able to make 2bn doses a year by mid-2021, thanks to a partnership with the Serum Institute of India.
Share price change in the past 12 months
The biggest financial gains will go to fund managers such as Vanguard and BlackRock, who are the biggest shareholders.8
CureVac expects to publish late-stage results for its CVnCov vaccine in April and hopes to gain EU approval by June. The EU has pre-ordered 225m doses with the option to buy a further 180m. Unlike other mRNA vaccines, CureVac’s shot can be stored at fridge temperature. Together with GSK, which owns nearly 10% of the German firm, it is seeking to develop next-generation shots for multiple emerging Covid-19 variants in one vaccine.
Expected sales in 2021: unclear – pricing not yet revealed, but priced at a profit
The Nasdaq-listed biotech aims to produce up to 300m doses this year and 600m to 1bn doses in 2022. CureVac says its jab requires less active ingredient than rivals but insists it cannot price it at cost because investors are expecting a return.
Share price change
The biggest shareholder is German billionaire Dietmar Hopp, the co-founder of the software firm SAP. He owns more than 80% of CureVac, now worth more than $12bn.
Vernon Coleman does his research on these companies.
Why would we trust these corrupt companies, where are the debates an proper discussions surrounding this? Today the Governments talking about obesity and what we should and shouldn’t put in our bodies, but this does not apply to the vaccines? #weainthavingit
As you probably already know, all of these manufactures of Covidian-vaccines and especially their investors are Eugenists
This Channel is banned throughout the EU, Aus. and Canada
please also follow me at ALTERNATE video platforms.
BitChute .. https://www.bitchute.com/channel/gIudfF6VnKd0/
UGET .. https://videos.utahgunexchange.com/@WardoRants
Freedom Social .. https://freedom.social/cmpgm/wardo
Social Media Sites
Minds .. https://www.minds.com/WardoRants/
Twitter .. https://twitter.com/wardo101
Gab .. https://gab.com/WardoRants
MiWe .. https://mewe.com/i/wardorants
Freedon Social .. https://freedom.social/cmpgm/wardo 5 months, 3 weeks ago
AstraZeneca Plc history, profile and corporate video
AstraZeneca Plc is a global research-based biopharmaceutical company, which primarily focuses on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. The company sells products under the brands Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on April 6, 1999 and is headquartered in London, the United Kingdom.“
AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK – two companies with similar science-based cultures and a shared vision of the pharmaceutical industry.
The merger aimed to improve the combined companies’ ability to deliver long term growth and enduring shareholder value through:
Global power & reach in sales and marketing
- Ability to deliver the potential of existing and future products through the power and reach of a combined global sales and marketing resource
- Widespread class coverage in key therapy areas, such as cardiovascular and respiratory disease, due to complementary nature of products
- Major primary care presence, particularly in gastrointestinal, cardiovascular and respiratory medicine
- Leading position in a number of specialist/hospital markets, including oncology and anaesthesia
Early on, the company had a history of playing it safe. In the 1970s, Astra saw the future of antidepressants. It developed the first selective serotonin reuptake inhibitor (SSRI) called zimelidine, and began selling it 1982. But the drug produced a rare side effect that could damage the nervous system, and the company recalled it a year later. By recalling zimelidine, it avoided potential catastrophic losses from possible lawsuits.
But it had already received harsh criticism for its involvement in scandals for its blockbuster antipsychotics, Seroquel and Seroquel XR. Critics say the company was more focused on maximizing profits while it still had the patent on the drug than on patient and trial participant safety.
In addition to paying $350 million to resolve more than 23,000 lawsuits that allege Seroquel can cause diabetes, the company paid to settle illegal marketing charges. It also faced a number of scandals including corrupt data in studies for marketing the drug to children, a sex scandal and a poorly run clinical trial that could have compromised patient safety and data reliability.
Marketing Seroquel for Children
Dr. Melissa DelBello was the lead author of a ground-breaking 2002 study that found AstraZeneca’s atypical antipsychotic Seroquel (quetiapine) was safe for use in children. AstraZeneca financed the study which included 30 children diagnosed with bipolar disorder. In the end, only eight children taking Seroquel completed the trial, and DelBello determined the study was inconclusive.
However, the study was published anyway and concluded Seroquel was more effective in children than a test group not receiving the drug. The publication led to a national recommendation that atypical antipsychotics be the leading choice for children with bipolar disorder.
FACTAstraZeneca covered up study results that revealed Seroquel was either inconclusive or harmful.
Other studies involving Seroquel produced inconclusive or harmful results. Those were never published. It was later revealed that AstraZeneca systematically covered up the results. A company email used as evidence in a court case revealed: “Thus far, we have buried trials 15, 31, 56. The larger issue is how do we face the outside world when they begin to criticize us for suppressing data.”
In 2002, U.S. Sen. Charles Grassley criticized DelBello for receiving at least $238,000 in consulting fees and travel costs from AstraZeneca.
After years of investigations, AstraZeneca paid a $520 million fine brought by the U.S. Department of Justice for promoting Seroquel for unapproved uses. The company also paid $647 million to settle global lawsuits for failing to warn the public of Seroquel’s side effects.
‘Sex-for-Studies’ Seroquel Scandal
In 2009, a Florida lawsuit claimed then U.S. medical director for Seroquel Dr. Wayne MacFadden had sexual relationships with a clinical researcher who wrote journal articles favorable to Seroquel and a medical marketer who promoted Seroquel. The case was one of 9,000 claiming people developed diabetes and gained weight while on the drug.
Plaintiffs said these relationships were improper because research was supposed to be independent of AstraZeneca. MacFadden also had sexual relationships with employees of competitors and asked for trade secrets, CBS News and MedPage Today reported.
“The mere existence of these relationships calls into question the integrity of the scientific work product of those involved,” according to documents written by plaintiffs’ attorneys in 2009.
E-mails also surfaced showing AstraZeneca’s publications manager John Tumas buried three clinical trials with unfavorable Seroquel clinical data.
Poorly Organized Clinical Trial
In 2014, a Seroquel XR trial for borderline personality disorder headed by Dr. S. Charles Schultz faced scrutiny because of poor oversight, the New York Times reported. AstraZeneca paid Schultz, the head of the department of psychiatry at the University of Minnesota, to conduct the trial. In addition, he received more than $112,000 for “speaking and consulting fees and other payments” from 2002 to 2007.
Because of lack of supervision, two participants at a facility for sex offenders were able to fake their way into the trial. One of these men slipped Seroquel XR to unsuspecting staff and residents. The men were removed from the trial, but no one followed up with an investigation.
Following the Seroquel XR trial debacle, Schultz stepped down as head of psychiatry at the university.
Despite the sloppy trial and about one third of the participants dropping out because of side effects, results published in the American Journal of Psychiatry showed the drug as a promising treatment for borderline personality disorder. AstraZeneca didn’t pursue formal approval from the FDA, however.
Prior to this trial, the University of Minnesota ran a Seroquel trial in 2004, and one participant, Dan Markingson, committed suicide while on the drug.
AstraZeneca’s Drug Side Effect Litigation
In addition to AstraZeneca’s antipsychotic controversy, it also faced growing legal problems from some of its blockbuster medications. People who took some of the company’s best-selling drugs say the drugmaker failed to warn of side effects.
The cholesterol drug Crestor (rosuvastatin) is used to prevent or treat heart disease, heart attacks and strokes.
People harmed by Crestor took AstraZeneca to court, claiming in lawsuits the drug contained dangerous defects. A consumer advocacy group also called for the recall of Crestor from the U.S. market but no recall was ordered.
Onglyza & Kombiglyze XR
The FDA approved Onglyza (saxagliptin) in 2009 to treat Type 2 diabetes. AstraZeneca and partner Bristol-Myers Squibb made hundreds of millions of dollars annually from Onglyza, but a study reported Onglyza increased the risk of hospitalizations due to heart failure. The FDA warned of the increased risk in April 2015.
A month later, a woman claimed her mother died from heart failure caused by Onglyza and filed a lawsuit against AstraZeneca. Now more lawsuits are mounting for Onglyza and heart failure.
The FDA rejected Bristol-Myers and AstraZeneca’s once-daily Farxiga (dapagliflozin) before approving it in 2014. The FDA had originally denied it because data in studies showed a possible risk of bladder cancer.
After the FDA released several warnings linking the drug to serious side effects, numerous law firms are analyzing cases from people who suffered from ketoacidosis, kidney problems, UTIs or other conditions possibly caused by Farxiga.
AstraZeneca’s Drug Pipeline
While AstraZeneca’s biggest sellers make billions for the company, it continues to look for ways to replace declining revenue from its core drugs losing patent. For instance, Crestor made $3.4 billion in 2016, but it was down from $8.5 billion in 2014. Nexium made $2 billion in 2016, but it was down from $7.7 million in 2014.
AstraZeneca’s purchase of Bristol-Myers’ diabetes division was one of many actions taken by pharmaceutical companies to consolidate their businesses into more specialized focus areas.
In 2017, the company announced it had 133 projects in its development pipeline. The majority of these drugs are treatments for cancer. But it is also looking for additional FDA approvals for currently existing drugs such as Nexium and its diabetes drugs (Farxiga, Kombiglyze and Xigduo).
For example, the company is investigating using Nexium in children and getting Farxiga approved for Type 1 diabetes in the U.S.
Johnson & Johnson
Johnson & Johnson Headquarters in New Brunswick, New Jersey
Boy, when I was growing up, if you saw that name on a product it meant healing and protection. A name you can trust. Every little kid felt so much better when Mommy put a “Bandaid” on their booboo. Everything Johnson & Johnson made we trusted. Trusted with our most precious treasure, our babies.
FOR DECADES!! We learned to trust and depend on Johnson ; Johnson. When I think of how many times in my life I watched people shaking that stuff on their babies and rubbing it all over their bodies with the dust flying in the air around the baby and the person applying it… I WANT TO SCREAM! When I think of all the ladies and girls who applied it all over their bodies, especially their private parts, so they could feel refreshed and smell sweet. I want to cry. Why?? Because Johnson ; Johnson knew all along that Talcum powder was dangerous, even deadly and they did not care. They were making too much money to care. They knew that it would take years for the symptoms to be clear and detectable. They knew they would have a good chance of beating any charges. They did their damnedest to cover up all the evidence.
I don’t have time to address this one company long enough… So, visit my article: Johnson and Johnson a name you can trust—-NOT!!! for more details.
Johnson & Johnson History
Robert, James and Edward Johnson founded Johnson & Johnson in 1886 in New Brunswick, New Jersey. The company focused on bandages, sterile sutures and wound care.
The company also sold women’s health products. These included sanitary protection products. It also sold maternity kits with first-aid products to make childbirth safer.
J&J created the first commercial dressings applied by consumers. We know this product made in 1921 as Band-Aids.
- ESTABLISHED 1886
- HEADQUARTERS New Brunswick, New Jersey
- 2017 REVENUE $76.45 billion
- FOUNDERS Robert, James and Edward Johnson
- SIZE More than 125,000 employees
- INCOME: J&J brought in more than $76 billion in 2017. It ranked No. 1 in annual revenue among its competitors.
- CEO: Alex Gorsky is its CEO. He is the seventh CEO to head J&J.
- SUBSIDIARIES:: Johnson & Johnson is a parent company for over 250 subsidiaries. Together, the companies make up “the Johnson & Johnson family of companies.”
- Popular J&J Products and BrandsInvokanasodium-glucose cotransporter 2 (SGLT2) inhibitor to treat Type 2 diabetesTylenolpain relieverLevaquinfluoroquinolone antibioticRisperdalantipsychotic drugTopamaxmedication used to prevent seizures and migrainesXareltoblood thinnerConcertaADHD drugPower Morcellatorsdevice used to remove fibroids
Notable Johnson & Johnson Recalls
Johnson & Johnson recalled some of its most popular products after patients reported injuries. The FDA and other government agencies investigated.Notable J&J Recalls (This is not an exhaustive list. Just the most “Notable”.)
- 1982 – MCNEIL
Product Recalled – Tylenol (acetaminophen) capsules
Reason for Recall – Medicine laced with potassium cyanide (poison)resulting in several patient deaths
- 2009 TO 2011 – MCNEIL
Product Recalled – Several OTC medicines including Tylenol, Motrin, Benadryl, St. Joseph aspirin, Sudafed, Pepcid, Mylanta, Rolaids, Zyrtec, Zyrtec Eye Drops(tens of millions of bottles)
Reason for Recall – Unpleasant smells causing nausea; tiny metal shards in liquid medicines; wrong ingredient levels
- 2010 – DEPUY [PINNACLE SYSTEMS]
Product Recalled – ASR Hip Resurfacing System and ASR XL Acetabular System(metal-on-metal hip implants)
Reason for Recall – Metal poisoning (metallosis); loosening of the implant or joint dislocation; additional surgeries
- 2012 – ETHICON
Product Recalled – Gynecare Prolift Kit, Gynecare Prolift+M Kit, Gynecare TVT Secure and Gynecare Prosima Pelvic Floor Repair System Kit (transvaginal mesh implants)
Reason for Recall – Perforation of organs; vaginal bleeding and scarring; mesh erosion; severe pain
- 2013 – MCNEIL
Product Recalled – Motrin (ibuprofen) for infants(200,000 liquid bottles)
Reason for Recall – May contain tiny particles of plastic
- 2013 – JANSSEN
Product Recalled – Risperdal Consta (injectable antipsychotic drug)(one lot)
Reason for Recall – Routine testing showed evidence of mold
- 2014 – ETHICON
Product Recalled – Power Morcellators
Reason for Recall –Spread of uterine cancer;rapid progression of the disease; death
- 2016 – ETHICON
Product Recalled – Physiomesh flexible composite hernia mesh
Reason for Recall – Studies showed higher revision rates after implant
- 2017 – STERILMED
Product Recalled – Agilis Steerable Introducer Sheath (hemostatic heart valve)
Reason for Recall – Device failure due to an improper seal of the sheath hub, which can allow blood leakage, device detachment during the procedure or development of an air embolism
Johnson; Johnson Lawsuits
J&J faced more than 100,000 lawsuits in March 2018 over claims its products are defective.
Lawsuits point to internal documents showing J and its subsidiaries knew about problems with their products but sold them anyway.Pending Lawsuits Against J&J
DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System Number of Lawsuits – More than 1,650
Injuries – dislocation, loosening, metallosis (metal poisoning), revision surgeries
Pinnacle Acetabular Cup Number of Lawsuits – More than 9,400
Injuries – dislocation, loosening, metallosis (metal poisoning), revision surgeries
Pelvic (Transvaginal) Mesh Number of Lawsuits – More than 24,000
Injuries – erosion, infection, pain, urinary problems, recurring prolapse, recurring incontinence
Risperdal Number of Lawsuits – 18,500
Injuries – enlargement of male breasts (gynecomastia), surgery to remove male breasts, emotional injuries, diminished quality of life
Xarelto Number of Lawsuits – More than 20,300
Inj uries – severe, sometimes deadly bleeding events, blood clots, wound leaks, infection
Opioids (Duragesic, Nucynta and Nucynta ER) Number of Lawsuits – More than 430
Injuries – addiction, overdose, respiratory depression, respiratory failure, death
Johnson’s Talcum Powder Number of Lawsuits – More than 6,550
Injuries – ovarian cancer, mesothelioma cancer
Major Johnson & Johnson Verdicts and Settlements
J&J was involved in sevenof 2017’s top ten health-care-related verdicts.
The company was also involved in the third-largest pharmaceutical settlement with the U.S. Department of Justice.In 2013, J&J paid the Justice Department more than $2.2 billion. The settlement resolved civil and criminal allegations involving Risperdal, Invega and Natrecor.Recent J Verdicts and Settlements
- FEBRUARY 2016A jury in Missouri ordered J to pay $72 million in a Johnson’s Baby Powder case.An appeals court tossed the verdict in 2017.
- MARCH 2016A jury in Texas awarded five patients $500 million in a Pinnacle hip implant case.State law required the award be cut to $150 million.
- DECEMBER 2016A jury awarded $1 billion to six patients in a Pinnacle hip implant case. A judge slashed the award to $543 million.
- APRIL 2017A jury in Philadelphia ordered J&J to pay $20 million in a transvaginal mesh lawsuit.
- MAY 2017A jury in Missouri awarded $110.5 million to a woman who developed ovarian cancer after using Johnson’s Baby Powder and Shower to Showertalcum powder. J&J planned to appeal the verdict.
- MAY 2017J paid $33 million to most U.S. states and the District of Columbia.The states charged J with misrepresenting the manufacturing practicesbehind certain drugs. This included its Motrin products. These products were later recalled.
- AUGUST 2017A California jury ordered J&J to pay $417 millionin a Johnson’s Baby Powder and talcum powder case. A trial judge overturned the verdict in October 2017 and ordered a new trial.
- NOVEMBER 2017A federal jury in Dallas ordered J&J to pay six patients $247 million in a Pinnacle hip implant case.J;J said it planned to appeal the verdict.
- DECEMBER 2017A federal jury in Philadelphia ordered J;J to pay $27.8 million in a Xarelto bleeding lawsuit. A judge overturned the verdict in 2018.
- DECEMBER 2017A New Jersey federal jury issued a verdict of $15 million against J;J in a Prolift pelvic mesh case.
- MARCH 2018An Indiana jury awarded a woman $35 million in a Prolift pelvic mesh case.J&J planned to appeal the verdict.
Please seek the advice of a medical professional before making health care decisions.
Johnson and Johnson have been found guilty of these crimes there is no doubt. Their power is getting a lot of the settlements reduced or overturned…That just shows you how much disrespect this company has for our judicial system and for the plaintiffs. It shows you just how much they care about you, the consumer. They lied to us for YEARS, and when they finally got caught, they want to be cleared of all responsibility. Is that who you want to trust with your medical care???
The US Merck is now called Merck & Co. (Kenilworth, NJ) in the US (and Canada), and MSD (Merck Sharpe and Dohme) in the rest of the world . Merck & Co. is a public corporation and its shares are traded daily on the NYSE under ticker symbol MRK. It is owned by its shareholders.
Merck & Co. manufactures a variety of well-known pharmaceutical drugs, vaccines and animal-health products. It made the first smallpox vaccine for commercial use in the U.S. It is also the maker of the painkiller Vioxx and the HPV vaccine Gardasil.
Merck & Co. manufactures popular pharmaceutical products for Type 2 diabetes, asthma and birth control. These products include Januvia, Singulair and NuvaRing.
The company also includes an animal health division. It makes vaccines for cattle and diabetes treatments for dogs and cats.
Merck is one of the largest pharmaceutical companies in the world. In 2017, it raked in over $40 billion in revenues.
But with all its successes, Merck has had its share of controversy and legal troubles as well. People who say the company’s products injured them have filed thousands of lawsuits against Merck.
The Big Pharma company has also faced patent lawsuits and criminal charges for illegal marketing and price gouging. Merck is probably most well-known for its Vioxx scandal.
Merck continues to develop new drugs for cancer and diabetes. The drug manufacturer also has some new vaccines in the works, including one for Ebola.
What Is Merck?
Merck is an American pharmaceutical company and one of the largest in the world.
The drug company has its headquarters in Kenilworth, New Jersey. It is a leader in the health care industry with a 125-year history.
Merck operates in more than 140 countries worldwide. It employs roughly 69,000 employees globally. Kenneth C. Frazier is CEO.
In 2017, it had revenues of $40.1 billion.
Outside the U.S. and Canada, Merck is known as Merck Sharp & Dohme.
Merck & Co. began in 1668 in Darmstadt, Germany.
Friedrich Jacob Merck opened the pharmaceutical company under the name Angel Pharmacy(Engel-Apotheke). He sold morphine, cocaine and codeine.
The company became a manufacturer in 1827. Heinrich Emmanuel Merck changed the course of the business under its new name E. Merck.
A U.S. sales office opened in 1887. And in 1891, the company’s U.S. branch Merck & Co. opened. George Merck, Heinrich’s grandson, headed its operation.
The U.S. branch of Merck grew. The company established a manufacturing facility in Rahway, New Jersey in 1902.
In 1917, after World War I, the government confiscated Merck; Co. and set it up as an independent company.
The original German Merck is now known as Merck KGaA.It has no affiliation with Merck ; Co.
Major Pharmaceutical Successes
Merck & Co. sold the first commercially used smallpox vaccine in the U.S. in 1898.
The next year, it published a guide for physicians and pharmacists known as The Merck Manual.
The manual is available in 17 languages today. It’s one of the most used texts in the world.
Merck agreed to merge with Philadelphia pharmacy Sharp & Dohme in 1953.
Together, the companies became the largest U.S. manufacturer of prescription drugs at the time.
Merck has more than 50 pharmaceutical products to its name.
The company specializes in products for cardiovascular, respiratory and infectious diseases. It also focuses on cancer, nervous-system disorders, immunology and women’s health.
Clinical studies link some of Merck’s pharmaceutical products to dangerous side effects. The U.S. Food and Drug Administration strengthened warnings for some of the drugs.Popular Merck PharmaceuticalsClarinex AntihistamineFosamax Slows bone lossImplanon Upper arm birth control implantJanuvia and Janumet Type 2 diabetes drugs (DPP-4 inhibitors)Keytruda Injectable cancer medicationNuvaRing Vaginal contraceptive ringPropecia Hair-loss prevention drugProventil Albuterol inhalerSingulair Asthma medicationZocor Cholesterol medicine (statin)
After solidifying its place in the pharmaceutical industry, Merck shifted focus to vaccines. In 1963, Merck manufactured the first measles vaccine. It made the first mumps vaccine in 1967.
Popular Merck VaccinesGardasil HPV vaccineMMR Measles-mumps-rubella vaccinePneumovax Pneumococcal vaccineRecombivax HBHepatitis B vaccineRotaTeq Rotavirus vaccineVarivax Chickenpox (varicella) vaccineZostavax Shingles (herpes zoster) vaccine
Merck Lawsuits and Settlements
Patients injured by Merck’s drugs have filed thousands of lawsuitsagainst the Big Pharma company. The drug maker has paid out billions of dollars in damagesto patients and their families as a result.
Merck paid millions in settlements and jury verdicts to thousands of people who say Fosamax caused their injuries.Multidistrict litigation (MDL) in New York over Dead Jaw Syndrome has mostly resolved.A second MDL in New Jersey for bone fractures involved more than 560 lawsuits as of May 2018. More Fosamax lawsuits are pending in multicounty litigation (MCL) and state courts.
Studies link Januvia to pancreatitis, pancreatic cancer and severe joint pain.According to lawsuits, some former Januvia users died after using the drug. A judge dismissed Januvia lawsuits in 2015. But as of 2018, an appeals court reinstated hundreds of pancreatic cancer lawsuits.
Organon, a subsidiary of Merck, manufactures NuvaRing, a birth control ring associated with life-threatening blood clots. Because of the possible side effects, the FDA released a drug safety communication in October 2011. People filed more than a thousand federal NuvaRing lawsuits.The company settled almost all of them for $100 million in 2014.
Merck changed Propecia’s label in 2011 to warn of the possibility of cancer and sexual side effects. It warned side effects may continue even after stopping treatment. As of May 2018, about 900 Propecia lawsuits remained pending in federal court in New York.
Vioxx is one Merck’s most well-known drug recalls.
Vioxx is a COX-2 inhibitor (pain reliever). It was linked to an increased risk of cardiovascular problems like heart attack and stroke.
The painkiller was on the market for five years before Merck pulled the plug. The FDA approved Vioxx in 1999. An estimated 25 million Americans used the drug.
Merck denied reports of dangerous cardiac side effects for years. But in September 2004, it pulled the drug from the market. It based its decision on findings from a clinical trial called APPROVe.
Vioxx was blamed for more than 3,400 deaths.
Merck paid nearly $7 billion to settle tens of thousands of Vioxx lawsuits and to cover civil and criminal fines.
DID YOU KNOW?Merck’s Vioxx settlement ended personal injury lawsuits brought by 47,000 people and about 265 potential class-action cases.
The federal government and Merck’s own shareholders targeted the company’s questionable business practices. They accused the company of tax fraud, price gouging, misleading shareholders and lying under oath.
Timeline: Business Practice Allegations Against Merck
- 2007The company agreed to pay $2.3 billion to settle a tax dispute with the Internal Revenue Service.
- 2008Merck paid $671 million tosettle federal health-care fraudclaims.
- 2013Merck paid $688 million tosettle two shareholder lawsuits.
- 2016Judge Beth Labson found Merck lied to the court and its business partner. Labson overturned a prior $200 m
Moderna From Wikipedia, the free encyclopedia
|Headquarters||200 Technology Square
Cambridge, Massachusetts 02139
Number of employees
|820 (Dec 2019)|
Moderna is an American biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA (mRNA). It is headquartered in Cambridge, Massachusetts. The Moderna technology platform is to insert synthetic mRNA into living cells that would reprogram the cells to develop immune responses, rather than being created externally and injected as with conventional medicines. It is a novel technique abandoned by several large pharmaceutical and biotechnology companies that were unable to overcome the side effects of inserting RNA into cells. As of May 2020, no mRNA drug has been approved for human use.
Moderna conducted mostly unsuccessful trials in traditional high-margin chronic therapeutic areas with AstraZeneca, and in orphan diseases with Alexion Pharmaceuticals. In 2014, Moderna moved to focus on lower-margin vaccines, given that an mRNA vaccine – efficacy issues aside – will always stimulate a level of antibody development in subjects. The strategic change led industry experts, and Moderna employees, to question the financial viability of the company.
In December 2018, Moderna became the largest biotech initial public offering (IPO) in history, raising US$600 million for 8% of its shares, implying an overall valuation of $7.5 billion, and with cumulative losses of $1.5 billion and equity raised of $3.2 billion, since inception. As of May 2020, Moderna was valued at $30 billion, but none of its mRNA molecules had reached large clinical trials, and several had failed due to side-effects. In July 2020, Moderna announced that its mRNA COVID-19 vaccine candidate in Phase 1 clinical testing had led to production of neutralizing antibodies in healthy adults.
In 2010, ModeRNA Therapeutics was formed to commercialize the research of stem cell biologist Derrick Rossi, who developed a method for modifying mRNA, transfecting it into human cells, then dedifferentiating it into stem cells that could then be further dedifferentiated into desired target cell types. Rossi approached fellow Harvard University faculty member Tim Springer, who called on Kenneth Chien, Bob Langer, and venture capital firm Flagship Ventures, to co-invest.
In 2011, the CEO of Flagship Ventures (now Flagship Pioneering), Noubar Afeyan, brought in European pharma sales and operations executive Stéphane Bancel as CEO. Afeyan personally owned 19.5% of Moderna and was the largest single shareholder, while his fund, Flagship Pioneering, owned 18%.
In March 2013, Moderna and AstraZeneca signed a five-year exclusive option agreement to discover, develop, and commercialize mRNA for treatments in the thereputic areas of cardiovascular, metabolic and renal diseases, and selected targets for cancer. The agreement included a $240 million upfront payment to Moderna, a payment that was “one of the largest ever initial payments in a pharmaceutical industry licensing deal that does not involve a drug already being tested in clinical trials”, and an 8% share in Moderna. As of May 2020, only one candidate has passed Phase 1 trials, a treatment for myocardial ischemia, labelled AZD8601.[a]
In January 2014, Moderna and Alexion Pharmaceuticals entered a $125 million deal for orphan diseases in need of therapies. Alexion paid Moderna $100 million for 10 product options to develop rare-disease treatments, including for Crigler-Najjar syndrome, using Moderna’s mRNA therapeutics platform  By 2016, Bancel told an audience of JPMorgan Chase investors that the work with Alexion would shortly enter human trials. However, by 2017, the program with Alexion had been scrapped as the animal trials showed that Moderna’s treatment would never be safe enough for use in humans.Most of the biotech community did not value vaccines. It was very hard to move that stuff forward. Because people said, “Oh, vaccines, nobody’s going to pay for that.” Jeff Ellsworth, Former Senior Director of Preclinical Pharmacology and Head of Rare Genetic Diseases, Moderna (2020)
In 2014, after disappointing standalone therapeutic trials,[b] Moderna moved to focus on mRNA vaccines given that, efficacy issues aside, mRNA will always stimulate a level of antibody development in subjects. The change in strategy had risk given the materially lower margins of vaccine development (called “loss-leaders” by some Moderna employees), with some senior employees and industry experts questioning the future viability of the company. Rossi left the company.
In February 2016, an op-ed in Nature, criticized Moderna for not publishing any peer-reviewed papers on its technology, unlike most other emerging and established biotech companies, and compared its approach to that of the controversially failed Theranos. In September 2018, Thrillist published article titled, “Why This Secretive Tech Start-Up Could Be The Next Theranos”, criticizing its reputation for secrecy and the absence of scientific validation or independent peer-review of its research, though having the highest valuation of any U.S. private biotech company at more than $5 billion. A former Moderna scientist told Stat: “It’s a case of the emperor’s new clothes. They’re running an investment firm, and then hopefully it also develops a drug that’s successful”.
In 2018 the company rebranded as “Moderna Inc.” with the ticker symbol MRNA, and further increased its portfolio of vaccine development. In December 2018, Moderna became the largest biotech initial public offering in history, raising $621 million (27 million shares at $23 per share) on the NASDAQ, and implying an overall valuation of $7.5 billion for the entire company. The year-end 2019 SEC filings showed that Moderna had accumulated losses of $1.5 billion since inception, with a loss of $514 million in 2019 alone, and had raised $3.2 billion in equity since 2010.
Moderna’s Company History
820+ (As of December, 2019)
200 Technology Square, Cambridge, MA
500 Technology Square, Cambridge, MA
One Upland Road, Norwood, MA
200,000 Sq Ft: R&D, New Venture Labs, and corporate offices in Cambridge, MA
200,000 Sq Ft: GMP mRNA clinical manufacturing facility in Norwood, MA
21 development candidates; 13 in clinical studies
Last Updated: January 2020
MODERNA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Moderna, Inc. – MRNA
NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (email@example.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-mrna/ to learn more.
The investigation concerns whether Moderna and certain of its officers and/or directors have engaged in fraud, negligence or other unlawful business practices.
On May 19, 2020, media outlets reported that vaccine experts had lodged criticism at the research intended to support the Company’s coronavirus vaccine candidate, based on insufficient data.
On this news, the price of Moderna’s shares plummeted over 20%, on heavier than average trading volume.
About Kahn Swick; Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Moderna, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or “the Company”) (NASDAQ: MRNA) for violations of the securities laws.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
The Schall Law Firm
Brian Schall, Esq.
Lipid Nanoparticle Delivery Technology for siRNA and mRNA Therapeutics
- FOUNDERSCharles Pfizer and Charles F. Erhart
- HEADQUARTERSNew York City
- SIZEMore than 90,000 employees
- 2017 REVENUE$52.5 billion
- SUBSIDIARIESAgouron Pharmaceuticals, G.D. Searle, GenTrac, Greenstone, Hospira, InnoPharma, Meridian Medical Technologies, Monarch Pharmaceuticals, Nordic Sales Group, Parke-Davis, Peak Enterprises, Roerig, Warner-Lambert, Wyeth, etc.
Pfizer: 7 Secrets You Didn’t Know (PFE)
Pfizer Inc. (NYSE: PFE) is the world’s 44th-largest public company, according to Forbes. As of July 31, 2018, Pfizer had a market capitalization of $225.7 billion. Pfizer’s roots date back to 1849, when two German-American entrepreneurs opened the company as a fine chemicals business, and it grew into a world-leading pharmaceuticals company that manufactures, markets, and distributes over 200 drugs in the United States.
Although many people are familiar with Pfizer and may use the company’s products, they may not be familiar with these interesting facts.
1. Pfizer Started in Brooklyn, New York
Cousins Charles Pfizer and Charles Erhart started Pfizer in the 1800s with $2,500 that Pfizer borrowed from his father. Thereafter, the cousins used the loan to open the chemicals business under the name of Charles Pfizer & Company. Pfizer operated in a red brick building located in Williamsburg, a neighborhood in Brooklyn, New York. The modest building served as Pfizer’s laboratory, factory, warehouse, and office.
2. Pfizer’s First Products and Innovation
Pfizer formulated its first product in 1849, which was an antiparasitic drug used to treat intestinal worms during the 1800s. Chemist Pfizer and confectioner Erhart naturally blended santonin with flavoring and shaped it into a candy cone. Pfizer launched the first domestic production of cream of tartar and tartaric acid, ingredients used heavily in the food and chemical industries. Pfizer expanded the production of tartaric acid and cream of tartar during the Civil War to support the Union Army.
3. Pfizer and Citric Acid
Pfizer began manufacturing citric acid using concentrates of lime and lemon in 1880. As soft drinks, such as those produced by The Coca-Cola Company (NYSE: KO), Dr. Pepper Snapple Group Inc. (NYSE: DPS) and PepsiCo Incorporated (NYSE: PEP), used citric acid in their formulas, the demand for the biochemical grew. Thereafter, Pfizer’s main product and growth stemmed from citric acid.
4. Pfizer’s Shift in Ownership and Incorporation
Erhart died on Dec. 27, 1891, and left his partnership, worth $250,000, to his son William Erhart. However, the agreement stated that Pfizer had the option to purchase William Erhart’s stake at 50% of the inventory. Pfizer exercised his option and became the sole owner of the company. Nine years later, Pfizer filed a certificate of incorporation in New Jersey with 20,000 shares issued at par value, or $100 per share. However, Charles Pfizer & Company remained a privately held company until 1942, when it issued 240,000 shares of common stock to the general public.
5. Pfizer Stealing Drug Secrets
Nonprofit Ischemia Research and Education Foundation filed a lawsuit against Pfizer in 2004, which alleged that Pfizer arranged a deal with lead statistician Ping Hsu at the Ischemia Research and Education Foundation to provide data. Additionally, the research foundation alleged that Pfizer stole trade secrets to develop Brextra, a pain medication. Pfizer and Hsu destroyed evidence that could have proven they stole trade secrets and used data without approval when the foundation confronted the two. On Dec. 24, 2008, a Santa Clara Country jury ordered Pfizer to pay $38 million to the Ischemia Research and Education Foundation for stealing drug secrets.
6. Pfizer’s Lobbying Expenses
Pfizer is one of the top pharmaceutical lobbying spenders and spends money lobbying for corporate tax cuts among other political topics. Pfizer spent $9.42 million in 2015, $9.88 million in 2016, and $10.43 million in 2017 on lobbying expenses. Pfizer’s lobby expenses are primarily spent on health and tax issues in recent years; however, in 2015 and 2016, its primary focus was on tax issues due to its aim to encourage U.S. tax reform.
7. Pfizer’s Acquisitions and Mergers
Pfizer made its first acquisition in 1953 and took over J.B. Roerig & Company, which specialized in nutritional supplements. J.B. Roerig became a division of the company and still plays an integral role in Pfizer’s marketing segment. In 1955, Pfizer partnered with Japanese drug company Taito to manufacture and distribute antibiotics. Nearly 30 years after the partnership, Pfizer acquired full ownership of Taito. Pfizer also acquired Mack Illertissen, a German pharmaceutical, chemical and consumer products company that focused on the needs of German consumers.
Pfizer acquired Warner-Lambert in 2000 for over $80 billion, bringing together two of the fastest-growing pharmaceutical companies at the time. That deal grew Pfizer’s global presence significantly and increased its product line, which now includes popular pharmaceutical products such as Listerine mouthwash. Pfizer’s most recent acquisition was the $14 billion deal to buy Medivation Inc., a US cancer drug company, in 2016.
Pfizer acquired several other companies over the years. Many of these companies made billions for Pfizer with their established research and drug development.
Warner-Lambert was one of these companies. It’s the original maker of Lipitor. Warner-Lambert merged with Pfizer in 2000.
Lipitor quickly grew to be the largest-selling pharmaceutical of any kind in history. It reached $9.6 billion in revenue in 2011.
Pfizer manufacturers and/or markets many well-known products. Studies link some of its products to serious side effects. The products prompted FDA warnings and lawsuits.
Popular Pfizer Products and BrandsNexium24HR Over-the-counter heartburn drugPrevnar 13 Vaccine to prevent pneumoniaAdvil Non-steroidal anti-inflammatory drug (pain reliever)Viagra Erectile dysfunction drugXanax Psychoactive medicineZoloft SSRI antidepressantLipitor Cholesterol medicineChantix Smoking cessation drugBextra Cox-2 inhibitor (pain reliever)Depo-Testosterone Testosterone replacement therapy drugEpiPen Auto-injector emergency allergy medicineCelebrex Non-steroidal anti-inflammatory drug (pain reliever)Zithromax Macrolide antibiotic (bacterial infections)Eliquis Anticoagulant (blood thinner)Protonix Proton pump inhibitor acid-reducerPrempro Hormone replacement drug therapyEffexor SNRI antidepressant
Pfizer Lawsuits and Settlements
Pfizer faces a growing number of lawsuits in 2018 involving some of its most popular drugs. In the past, courts dismissed thousands of lawsuits against Pfizer. The company also agreed to settle cases over illegal marketing and health care fraud.
PFIZER SETTLEMENT AND FINEPfizer set a record for the largest health care fraud settlement and the largest criminal fine of any kind with $2.3 billion in 2009.
People are suing Pfizer over Protonix. Protonix lawsuits say Pfizer failed to warn about the risk of kidney problems. In 2013, Pfizer agreed to pay $55 million to settle criminal charges. The U.S. Department of Justice said Wyeth promoted Protonix for unapproved uses in 2000 and 2001. Pfizer acquired Wyeth in 2009.
Nearly 10,000 women filed Prempro breast cancer lawsuits against Pfizer. By 2012, Pfizer settled most of the claims for more than $1 billion.
About 3,000 people filed Chantix lawsuits against Pfizer. They claimed Chantix caused suicidal thoughts and severe psychological disorders. In 2013, the company set aside about $288 million to resolve these cases. One case settled for an undisclosed amount just before trial in 2012.
More than 6,000 testosterone therapy lawsuits were pending in May 2018. The lawsuits say testosterone products caused strokes, blood clots and heart attacks.
A federal panel closed the consolidated Effexor litigation in 2013. Lawsuits claimed birth defects.
A judge dismissed Zoloft cases in 2016. Lawsuits included similar claims to Effexor XR. The judge did not disagree that Zoloft caused birth defects. But the judge concluded there was insufficient evidence to definitively link the two.
A judge dismissed a group of federal Eliquis cases in 2017. Injured patients continue to file severe bleeding claims in Delaware state court.
A judge dismissed Lipitor lawsuits in 2017. Women who took the drug filed lawsuits after developing Type 2 diabetes. There is currently an appeal pending.
Pfizer Drug Recalls
Pfizer has had to recall some of its popular products due to quality issues and poor packaging. Effexor XR and Prempro are two products affected by recalls.
In 2013, Pfizer announced it was recalling five lots of Prempro. Prempro is a hormone replacement therapy drug. Routine testing revealed the strength of the drug was low.
In 2014, Pfizer recalled two lots of its antidepressant drug Effexor XR. Tikosyn was discovered in an Effexor XR bottle. Tikosyn is one of the company’s heart pills. Pfizer warned that the combination of the two different drugs could be deadly.
In 1996, Pfizer conducted an unapproved clinical trial. It involved children with meningitis in Nigeria, CBS News reported. The trials led to the deaths of 11 children. Dozens more were left disabled.
PFIZER’S UNAPPROVED CLINICAL TRIALThe unauthorized trial involved tests on 200 children with Pfizer’s antibiotic Trovan.
Trovan is a drug severely restricted in use because of its potential to cause liver damage. Injury to the liver as a result of taking Trovan can lead to liver failure and death.
In 2011, Pfizer paid $700,000 to four families who lost children during the Trovan trials.
In addition, the company set up a $35 million fund for those affected by Trovan. Pfizer also agreed to sponsor health projects in Kano, Nigeria.
You must be aware that besides the drug companies themselves there are other entities with vested interest in the development of drugs and other products. These entities are most concerned with the development of the COVID 19 Vaccine. This vaccine is expected to include nanotechnology that will enable all kinds of digital functions including TRACKING.
One such entitiy is DARPA. Defense Advanced Research Projects Agency THIS OUGHT to bring you deep concern.
Make This Go Viral! Another Doctor Exposed! Bill Gates Wicked Agenda On Depopulation of the World
The House Energy and Commerce Committee is holding a hearing Tuesday with executives from five top drug companies on efforts to create a vaccine to prevent Covid-19. The companies — AstraZeneca, Johnson & Johnson, Merck, Moderna and Pfizer — are emphasizing to members of Congress that scientists can create a coronavirus vaccine in record-time while also ensuring that it is both safe and effective, according to written testimony submitted ahead of the hearing.
This video still works. Just click this link to watch it: https://youtu.be/Ka5wWJwIJ10
WATCH LIVE: Pharma Executives testify at Coronavirus hearing on Vaccines – 7/21/2020
I am so very thankful that President Trump has been moving us out of the grip of the United Nations. He has made a stand against this Medical Tyranny and cut ties with the UN World Health Organization.
Keep our President up in prayer. His life is in jeopardy!
Trump says US will cut ties with World Health Organization
Following through on a threat he made earlier this month, President Donald Trump today announced that the United States will cut ties with the World Health Organization (WHO).
In other pandemic developments, Moscow nearly doubled its COVID-19 death total, following questions about its counting method
The global total today climbed to 5,885,490 cases, and at least 363,031 people have died from their infections, according to the Johns Hopkins online dashboard.
WHO announcement follows repeated criticisms
Trump made the announcement today at a Rose Garden media briefing where he took no questions afterward from the media. During his address today, he claimed that China has control over the WHO, while only paying $40 million a year compared with the US contribution of $450 million.
Over the past few months and amid others criticizing his own COVID-19 response, Trump has accused the WHO of being slow with its response and for not being tough enough on China in demanding more answers on the source of the virus. Trump’s pressure on the WHO is also part of broader political tensions between the United States and China, though earlier in the outbreak, Trump praised China President Xi for his handling of the outbreak.
The issues came to a head about 2 weeks ago when Trump sent WHO Director-General Tedros Adhanom Ghebreyesus, PhD, a letter threatening to make US funding cuts permanent and reconsider participation in the body unless the WHO committed to “major substantive improvements” in the next 30 days.
Tedros has repeated at recent media briefings that he is considering the contents of the letter, and on May 19, the World Health Assembly passed a multipart resolution that included several COVID-19 issues, one of which was a call for an independent inquiry into the pandemic and for the WHO to investigate the source of the virus.
The WHO has no authority under International Health Regulations to do its own investigations within member countries, but China this month agreed with the need for an independent probe as soon as the pandemic threat is over. (knowing full well they don’t intend for the “THREAT” to ever be over.) The agency has also vigorously pushed back against Trump’s criticisms and has urged countries not to politicize the pandemic.
In April, Trump announced a freeze on US funds to the WHO, a significant development, given that the country is the WHO’s biggest funder. Earlier this week, the WHO announced the creation of a new funding group called the WHO Foundation, which was 2 years in the making and designed to grow support from sources it hasn’t tapped before to help support its global health activities and create more stable, flexible funding for its programs.
Sharp public health blowback
Trump’s announcement today drew strong condemnation from many public health experts, who called the move unwise, especially in the middle of a pandemic. On Twitter, Tom Frieden, MD, former director of the US Centers for Disease Control and Prevention (CDC) (another group that needs to be defunded.) and president and chief executive officer of Resolve to Save Lives, said, “We helped create WHO. We are part of it. It is part of the world. Turning our back on WHO makes us and the world less safe.” (BULL, The WHO is working to bring the world under a totalitarian dictatorship using Medical Tyranny)
The WHO, part of the United Nations, was established in 1948 and traces its roots to the Pan American Health Organization. As the leading health agency in the response to infectious diseases such as Ebola, malaria, and tuberculosis, it also works on noncommunicable diseases and other health issues, such as substance abuse. It relies on assessed and voluntary contributions from its member states. (Well, we can see that they have been totally useless. Substance abuse is at an all time high and continues to climb, infectious diseases are off the chart.)
Lawrence Gostin, JD, of the O’Neill Institute for National and Global Health Law and Georgetown University Law Center, on Twitter today called Trump’s US withdrawal announcement “unlawful and dangerous.” (Some of the NON Governmental Groups working to undermine National Government and force us into a World Dictatorship)
He said the move is unlawful, because the United States had treaty obligations under the WHO constitution and International Health Regulations and because the action requires Congress, which has already allocated funds. He said the step is dangerous, because the world is in the middle of a pandemic. (Once again, I am so thankful for a President who is willing and able to stand up for what is right and against the corporate entities who rule us.)
Michael Osterholm, PhD, MPH, director of the Center for Infectious Disease Research and Policy (publisher of CIDRAP News), said that today is a very sad day for the public’s health. He said the WHO isn’t perfect, but it plays a critical role in the world. “We will all pay a price down the road for this decision,” he said. “An infectious disease anywhere in the world can be everywhere in the world.” (scare tactics. I for one celebrate one step towards being freed from the long reaching arm of the United Nations.)
He said he worries about the action’s consequences on WHO funding, as well as the loss of in-kind support from US experts who work closely with the WHO and support its scientific and public health mission. “Their status is unclear,” Osterholm said. (GOOD! I hope they crash and burn. America has always cared about helping people’s and nations that are less able to help themselves. I bet you we can do better with that $450 million than the WHO has ever done.)
The president of the Infectious Diseases Society of America (IDSA), Thomas File, Jr, MD, also spoke out today on Trump’s announcement in a statement sent to journalists. “As infectious diseases physicians on the front line of combating the current global crisis, we stand strongly against President Trump’s decision to leave the World Health Organization,” he said, adding that the pandemic shows that neither boundaries nor politics can protect against infectious disease spread.
“We will not succeed against this pandemic, or any future outbreak, unless we stand together, share information, and coordinate actions.” (Once again, scare tactics. I have faith in our President and I have faith in the American people. More importantly, I have faith in GOD.)
Technology sharing tool launches; Moscow revises death count
In other pandemic developments today, the WHO and Costa Rica led the launch of a COVID-19 Technology Access pool, which Tedros said is a sister initiative to the Access to COVID-19 Tools (ACT) Accelerator, an $8.1 billion effort to speed the development and equitable access to new tools to battle COVID-19.
The access pool, which is voluntary, will provide a one-stop to share scientific knowledge, data, and intellectual property.
Moscow, meanwhile, more than doubled its number of deaths for April following criticism of its data that said Russia relied on a different counting method, Reuters reported today. Moscow, the country’s hot spot, now reports 1,561 deaths, compared with 636 initially reported for April. The new number includes people with COVID-19 who died from other causes and those who died from suspected infections.
Twitter yesterday applied a fact-checking label on two tweets from a Chinese foreign ministry spokesman who claimed that the US Army carried SARS-CoV-2 to Wuhan, CNET reported.
In South Korea, more than 500 schools in Seoul closed today, shortly after reopening, as part of measures related to a flare-up of COVID-19 cases in the city linked to nightclub outbreaks and a big cluster at an e-commerce warehouse, CNN reported.